Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

LEGN 10.03.2024

Full Press ReleaseSEC FilingsOur LEGN Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual JP Morgan Healthcare Conference
  • 12.19.2024 - Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.10.2024 - CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Recent Filings

  • 01.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 144 Report of proposed sale of securities
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader

SOMERSET, N.J.,Oct. 03, 2024(GLOBE NEWSWIRE) --Legend Biotech Corporation(NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility inPhiladelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.

“This new facility underscores Legend’s commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation,” saidYing Huang, Ph.D., Chief Executive Officer ofLegend Biotech. “We are excited to join thePhiladelphiabiotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partnerships with local, leading research institutions. We look forward to bolstering our cell therapy capabilities at this new site.”

The newPhiladelphiafacility adds to Legend’s existing global R&D organization, which encompasses more than 350 employees across the globe. The 31,000-square-foot facility at2300 Market Streetis expected to be complete in the third quarter of 2025. Legend, which has over 1,200 employees inthe United States, anticipates 55 full-time employees will eventually be based in thePhiladelphiafacility. This expansion builds on Legend’s existing R&D footprint in theU.S., including a facility inPiscataway, New Jersey.

“Legend’s investment in this new site will offer our world-class research team an optimal environment and resources to expand on our cutting-edge innovation,” saidGuowei Fang, Ph.D., Chief Scientific Officer and Head of Business Development ofLegend Biotech. “We are particularly enthusiastic about the proximity to leading academic institutions inPhiladelphiathat are at the forefront of medical breakthroughs as we focus on advancing our sustainable pipeline of innovative cell therapies.”

AboutLegend BiotechLegend Biotechis a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered inSomerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more atwww.legendbiotech.comand follow us onX (formerly Twitter)andLinkedIn.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSStatements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in theU.S.litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with theSecurities and Exchange CommissiononMarch 19, 2024. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release.Legend Biotechspecifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

INVESTOR CONTACT:Jessie YeungTel: (732) 956-8271jessie.yeung@legendbiotech.com

PRESS CONTACT:Mary Ann OndishTel: (914) 552-4625media@legendbiotech.com

Primary Logo

Source: Legend Biotech USA Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com